$UNIS Email Signup Form

$UNIS @ Stock Twits

Industry Associations

Contact Unilife

Unilife Corp

250 Cross Farm Lane
York PA 17406 USA
T + 1 717 384 3400


Disclaimer

Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS)

unis

Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit www.unilife.com.

More than two billion prefilled syringes are currently used each year on a global basis and pharmaceutical companies are making the switch to products such as Unilife's safety syringe which are compliant with needle-stick prevention laws (e.g. Federal Needlestick Prevention Act, 2000).

Key differentiating features of Unilife's fully-integrated (within the barrel of the syringe) safety syringes include the following:

  1. A passive needle retraction system that is activated inside the body;
  2. Healthcare providers / shot administrators control the speed of needle retraction;
  3. Auto-disabling prevents re-use or tampering with used syringes.

The market opportunity for prefilled syringes includes 50 drugs (primary anti-coagulant / hematology medications, vaccines, and other biological agents) that are delivered by injection, including an estimated 3 billion prefilled syringes in use by 2012.

Unilife has a distinct advantage with a disruptive technology since there are currently no prefilled syringes to deliver medications with fully-integrated safety features so pharmaceutical companies must add these features - which adds to production / shipping costs and increases the overall packaging size by up to 60%, resulting in both waste disposal and marketing issues.

Unilife Corp ($UNIS) @ Morgan Stanley Healthcare Conference 2011

CEO Alan Shortall on CNBC's Mad Money with Jim Cramer on June 21, 2011

The Unifill Syringe

On Track - Milestones update June 2011

An Expanding Opportunity

UNIS @ Wikinvest

York, PA Building Video

Griffin Securities - June 2011 Update on UNIS

Unilife @ Yahoo Finance (NASDAQ: UNIS)

Thu, 17 May 2012 17:05:35 GMT
Thu, 10 May 2012 20:21:52 GMT
Sunday, Apr 29, 2012
Sat, 28 Apr 2012 13:40:58 GMT
Thu, 26 Apr 2012 21:31:53 GMT
Thu, 26 Apr 2012 20:05:00 GMT
[PR Newswire] - YORK, Pa., April 26, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended March 31, 2012 ...
Thursday, Apr 26, 2012
Wed, 18 Apr 2012 21:25:00 GMT

Unilife @ Cowen Healthcare - March 2011

Unilife follow-up interview with Cramer on The Street.com TV

Unilife CEO Video Interview on CNBC

Unilife Medical Blog

Current Articles | RSS Feed RSS Feed

Med Students' Needle-Handling Error Exposes Patients to Potential Infection #ProActiveNR $UNIS

  
  
  
  

Sent to me by a Unilife investor:

The Associated Press is reporting that a group of medical students at the University of New Mexico School of Medicine in Albuquerque did not properly change out needles on medical devices used to test blood glucose levels, thus putting as many as 50 patients at risk for contracting bloodborne pathogens.

The University of New Mexico School of Medicine has posted the following announcement on its Web site:

“On Saturday, April 24, 2010, a group of students from the University of New Mexico Physician Assistant program were volunteering at the Indian Pueblo Cultural Center in Albuquerque during the Center’s American Indian Week “Pueblo Days” to offer free voluntary blood sugar tests. The device used to prick the finger to get the blood sample required for testing was meant for single patient use and not for multiple patients. Those who volunteered for testing that day may have been put at risk of contracting infections due to potential exposure to diseases spread by blood contact. “Despite direct faculty supervision, three mistakes were made: They used the wrong device; they were not all properly trained on the device; no records of those tested were kept.

“We estimate that 51 to 55 individuals were tested, potentially exposing these people to other's blood. The diseases of greatest concern are hepatitis B and C although theoretically HIV is also possible. Our best current assessment of the risk of infection is less than a 0.5 percent risk. Even though the risk is small it is something we are very concerned about it and are taking it seriously.

“UNM School of Medicine deeply regrets this error and wants to apologize to all those who may have been exposed, and to the Indian Pueblo Cultural Center. We are asking that those who were tested come forward so we can better assess any risk from this episode and assure that exposed persons receive appropriate follow-up testing and care. If you know someone who was tested please contact us.

“Those who may have been exposed will be offered follow-up testing for Hepatitis B, C, and HIV. The costs of testing will be covered by UNM.

“Public health authorities are requesting that those who participated in the diabetes screening event should contact 1-888-899-6092 for more information and referral for screening. You may also use this web form to make contact.”
 

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics